Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Operating Income Loss of -$472.13 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -10.9% in Operating Income Loss from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 2,738.9%.
- Historical annual values: Fiscal year 2025: -$472.13 million | Fiscal year 2024: -$425.74 million | Fiscal year 2023: -$391.49 million | Fiscal year 2022: -$389.05 million | Fiscal year 2021: -$378.42 million | Fiscal year 2020: -$335.92 million | Fiscal year 2019: -$316.27 million | Fiscal year 2018: -$362.48 million | Fiscal year 2017: -$320.79 million | Fiscal year 2016: -$200.99 million | Fiscal year 2015: -$118.70 million | Fiscal year 2014: -$54.13 million | Fiscal year 2013: -$38.88 million | Fiscal year 2012: -$23.00 million | Fiscal year 2011: -$16.63 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: